Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. Today, worldwide more than 6,900 employees are working on this permanent challenge at over 90 locations on all continents. Bruker continues to build upon its extensive range of products and solutions, its broad base of installed systems and a strong reputation among its customers.
Find locations served, office locations and our distributors
- Business Type:
- Industry Type:
- Laboratory Equipment
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Over 50 years of innovation
The Bruker Corporation owes its existence to Professor Günther Laukien who already in the 1950s recognized the need for impulse spectrometers. In 1960, Professor Laukien set out to fill this need by establishing Bruker Physik-AG in Karlsruhe. Since there, Bruker has been developing groundbreaking analytical solutions.
Around that time, laboratories in the US were already building the first high-resolution NMR systems for use in analytical chemistry. Prof. Laukien recognized the power in this technique and the need for an impulse spectrometer not yet produced commercially. He set out to fill this need by establishing his own company.
During the 1960’s, it became evident that to be a key player in the analytical instrument market, an increased global presence was needed with service and support for customers and researchers at a local level.
The first step in this direction had been made with the establishment of an office in North America, a growing center of NMR research. Despite the initial dominance of US-based companies, Bruker grew rapidly due to its technological superiority and its widespread acceptance within the NMR community.
Soon, Bruker SA was established in France, where facilities in Wissenbourg began to produce system components and sub-assemblies. The establishment of additional sales offices in Europe, including the UK and Italy, continued through the late 1960s and early 1970s.
In 1969, during the 25th anniversary of the discovery of EPR in Kazan Russia, Bruker announced further expansion into what was then the USSR. A new office was also established in Israel, further strengthening an already-established relationship with the Weizman Institute.
By 1972, Bruker’s expansion had reached Australia, and in 1975 Bruker arrived in China, where a successful appearance at the Swiss Industrial Exhibition in Beijing resulted in the immediate sale of two WH 90 systems—the first FT-only NMR spectrometers. South Korea and Taiwan sales offices soon followed, and in 1976 Bruker opened its first facility in Japan. Bruker was also successful in South America, with the first instrument installations taking place in Venezuela.
During this time of rapid global expansion, it became apparent that further growth in the market of analytical instrumentation would require the expansion into additional and new analytical technologies.
Bruker’s already established strengths in NMR naturally led to developments in the field of Magnetic Resonance Imaging (MRI). Bruker Medizintechnik (Medical) GmbH was formed in 1976, initially offering a range of mobile defibrillators. Later in the decade, Bruker had developed and was producing NMR-based tomography systems for use in clinical and pre-clinical applications, leading eventually to whole-body clinical MRI instrumentation.
Over time, Bruker chose to shift its focus towards pre-clinical systems and became Bruker BioSpin MRI, the currently market leader in the field.
In 1977 “Dr. Franzen Analysentechnik” was founded in Bremen as a spin-off company from Atlas MAT. A few years later, in 1980, Bruker acquired this company and renamed it “Bruker-Franzen Analytik”, adding robust quadrupole mass spectrometers to the Bruker portfolio. That same year the first mobile detection system, the MM1, proved successful in both the civilian and military markets. In 1997 Bruker-Franzen Analytik GmbH was renamed Bruker Daltonik GmbH. The name was chosen to honor John Dalton for his work in formulating the theory of the atomic structure of matter. The development of two new ionization procedures in the late 1980s, electrospray and MALDI, enabled the ionization and analysis of biomolecules. This paved the way for the application of mass spectrometry in molecular biology and molecular medicine. With the spectrometers being continuously enhanced, Bruker mass spectrometry experienced unexpected growth.
In 1997 Bruker acquired the X-ray spectroscopy division of Siemens AG, which included prime manufacturing facilities in Karlsruhe and Madison, Wisconsin. Commercial growth, combined with additional company acquisitions, quickly launched Bruker AXS as a leading provider of X-ray analytical instrumentation, significantly extending Bruker’s technology portfolio.
Unification under a single parent company—the Bruker Corporation (NASDAQ: BRKR) created one of the strongest brands in analytical instrumentation.´